A Comprehensive Meta-analysis of Efficacy, Cardiovascular Protection, and Emerging Therapeutic Innovations of Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have completely changed the way type 2 diabetes mellitus (T2DM) is treated. They offer a wide range of benefits, including protecting the heart and metabolism as well as controlling blood sugar levels. This systematic review and meta-analysis amalgamates data from randomized controlled trials and observational studies published from 2014 to 2024 to thoroughly assess the relative efficacy, safety, and clinical significance of GLP-1 RAs in the management of T2DM. We systematically searched electronic databases such as PubMed, Embase, Cochrane CENTRAL, and Web of Science. The quantitative synthesis incorporated forty-two eligible studies with a total of 68,451 participants. We used random-effects meta-analysis models with weighted mean differences (WMD) and risk ratios (RR) with 95% confidence intervals (CIs) to pool the data. GLP-1 RAs caused significant drops in hemoglobin A1c (HbA1c) (WMD = −0.91%; 95% CI: −1.05 to −0.77%), body weight (WMD = −3.2 kg; 95% CI: −3.8 to −2.6 kg), and systolic blood pressure (WMD = −2.7 mmHg; 95% CI: −3.5 to −1.9 mmHg). These drugs significantly reduced the risk of major adverse cardiovascular events (MACE) (RR = 0.86; 95% CI: 0.82–0.91) and cardiovascular mortality (RR = 0.87; 95% CI: 0.80–0.94). Gastrointestinal adverse effects, such as nausea and vomiting, were the most frequently reported, although they were typically mild and transient. This body of evidence supports GLP-1 receptor agonists as essential elements in the contemporary management of T2DM, particularly for patients with cardiovascular disease or obesity. Dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) and the new triple GLP-1/GIP/glucagon agonists provide better treatment options and better metabolic effects. It is still very important to choose treatments based on each patient’s unique needs, other health problems, and treatment goals.